Acute lipid profile changes in malaria patients - a gateway towards novel antimalarial drug class identification?

Withdrawn

• Conditions: jungle fever; 10019815; Tropical fever

• Registration Number: NL-OMON44881
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 180

Inclusion Criteria

Patients > 18 jaar gedianosticeerd met malaria
Controls > 18 jaar with acute symptoms

Exclusion Criteria

chronic lipid metabolic disorder
chronic use of medication

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measure is the plasma lipid profile. Full plasma lipid<br /><br>analyses (total cholesterol, HDL, apolipoprotein A1, LDL, VLDL and<br /><br>triglycerides) will be conducted in both maparia patient and control groups.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary outcome measures in the patient group are hemozoin quantity<br /><br>proxies as outlined above, in correlation with parasite density, and clinical<br /><br>characteristics as obtained in the framework of routine clinical care.</p><br>